Literature DB >> 17426928

Proteomic analysis of MOLT-4 cells treated by valproic acid.

Jirina Vávrová1, Sylva Janovská, Martina Rezácová, Lenka Hernychová, Zuzana Tichá, Doris Vokurková, Darina Záskodová, Emilie Lukásová.   

Abstract

The effect of valproic acid (VA) on protein expression in human T-lymphocytic leukemia cells MOLT-4 was studied. VA is an inhibitor of histonedeacetylases and has a potential use as antitumor agent in leukemia treatment. The authors in this work prove that 4 h long incubation with 2 mmol/l VA causes phosphorylation of histone H2A.X and its colocalization with 53BP1 in nuclear foci. Their co-localization is typical for DSB signaling machinery. These foci were detected in cells after 4 h exposure without increase of Annexin V positive apoptotic cells. Slight increase in apoptosis (Annexin V positivity) after 24 h is accompanied by more intensive increase in phosphorylation of H2A.X and also by formation of nuclear foci containing gammaH2A.X and 53BP1. Treatment of cells with 2 mmol/l VA resulted in induction of apoptosis affecting about 30% of cells after incubation for 72 h. The changes in protein expression were examined after cell incubation with 2 mmol/l VA for 4 h. Proteins were separated by two-dimensional electrophoresis and quantified using image evaluation system. Those exhibiting significant VA-induced abundance alterations were identified by mass spectrometry. Changes in expression of 22 proteins were detected, of which 15 proteins were down-regulated. Proteomic analysis resulted in successful identification of three proteins involving alfa-tubulin 3, tubulin-specific chaperone and heterogeneous nuclear ribonucloprotein F. Expression of seven proteins was up-regulated, including heterogeneous nuclear ribonucloprotein A/B. Identified proteins are related to microtubular system and hnRNP family. Suppression of microtubular proteins and changes of balance among hnRNPs can contribute to proliferation arrest and apoptosis induction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17426928     DOI: 10.1007/s11010-007-9455-0

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  26 in total

1.  Genes modulated by histone acetylation as new effectors of butyrate activity.

Authors:  F Della Ragione; V Criniti; V Della Pietra; A Borriello; A Oliva; S Indaco; T Yamamoto; V Zappia
Journal:  FEBS Lett       Date:  2001-06-22       Impact factor: 4.124

Review 2.  The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression.

Authors:  Brian Carpenter; Catriona MacKay; Ayham Alnabulsi; Morven MacKay; Colin Telfer; William T Melvin; Graeme I Murray
Journal:  Biochim Biophys Acta       Date:  2005-11-15

3.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells.

Authors:  M Göttlicher; S Minucci; P Zhu; O H Krämer; A Schimpf; S Giavara; J P Sleeman; F Lo Coco; C Nervi; P G Pelicci; T Heinzel
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

4.  Effect of valproic acid and antiapoptotic cytokines on differentiation and apoptosis induction of human leukemia cells.

Authors:  M Rezácová; J Vávrová; D Vokurková; D Záskodová
Journal:  Gen Physiol Biophys       Date:  2006-03       Impact factor: 1.512

Review 5.  Histone deacetylase inhibitors in clinical development.

Authors:  Roberto R Rosato; Steven Grant
Journal:  Expert Opin Investig Drugs       Date:  2004-01       Impact factor: 6.206

6.  Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines.

Authors:  Judit P Banáth; Susan H Macphail; Peggy L Olive
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 12.701

7.  Inhibition of tubulin assembly and covalent binding to microtubular protein by valproic acid glucuronide in vitro.

Authors:  Graeme R Cannell; Mark J Bailey; Ronald G Dickinson
Journal:  Life Sci       Date:  2002-10-18       Impact factor: 5.037

8.  'Catalysts' for polyacrylamide gel polymerization and detection of proteins by silver staining.

Authors:  D F Hochstrasser; C R Merril
Journal:  Appl Theor Electrophor       Date:  1988

9.  Effect of valproic acid, a histone deacetylase inhibitor, on cell death and molecular changes caused by low-dose irradiation.

Authors:  Darina Záskodová; Martina Rezácová; Jirina Vávrová; Doris Vokurková; Ales Tichy
Journal:  Ann N Y Acad Sci       Date:  2006-12       Impact factor: 5.691

10.  Heterogeneous nuclear ribonucleoproteins F and H/H' show differential expression in normal and selected cancer tissues.

Authors:  Bent Honoré; Ulrik Baandrup; Henrik Vorum
Journal:  Exp Cell Res       Date:  2004-03-10       Impact factor: 3.905

View more
  4 in total

1.  2D-difference gel electrophoretic proteomic analysis of a cell culture model of alveolar rhabdomyosarcoma.

Authors:  Joseph G Pressey; Christine S Pressey; Gloria Robinson; Richie Herring; Landon Wilson; David R Kelly; Helen Kim
Journal:  J Proteome Res       Date:  2011-01-10       Impact factor: 4.466

2.  The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells.

Authors:  Anna Scuto; Mark Kirschbaum; Claudia Kowolik; Leo Kretzner; Agnes Juhasz; Peter Atadja; Vinod Pullarkat; Ravi Bhatia; Stephen Forman; Yun Yen; Richard Jove
Journal:  Blood       Date:  2008-03-18       Impact factor: 22.113

3.  Endogenous HIV-1 Vpr-mediated apoptosis and proteome alteration of human T-cell leukemia virus-1 transformed C8166 cells.

Authors:  Fang He; Yaoying Zeng; Xiaoping Wu; Yuhua Ji; Xianhui He; Thomas Andrus; Tuofu Zhu; Tong Wang
Journal:  Apoptosis       Date:  2009-10       Impact factor: 4.677

4.  Laser capture microdissection and genetic analysis of carbon-labeled Kupffer cells.

Authors:  Stephan Gehring; Edmond Sabo; Maryann E San Martin; Elizabeth M Dickson; Chao-Wen Cheng; Stephen H Gregory
Journal:  World J Gastroenterol       Date:  2009-04-14       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.